“Novo Nordisk heard loud and clear the impact to the 15,000 Australians living with diabetes who depended on FIASP, if FIASP was no longer available on the PBS. We are pleased that patients can continue accessing this treatment on the PBS,” said Cem Ozenc, corporate vice president and general manager of Novo Nordisk Oceania. …
Patients win reprieve with Novo Nordisk listing a new form of insulin aspart
September 17, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial
November 13, 2025 - - Australian Biotech -
Australia joins global WHO task force to tackle antimicrobial resistance
November 13, 2025 - -
New post-market review workplan focuses on real-world data and patient outcomes
November 13, 2025 - - Latest News -
Government adds new first-line treatment to the PBS for deadly blood cancer
November 13, 2025 - -
RAGE Biotech raises $29 million and appoints new leadership to advance precision RNA therapeutics
November 13, 2025 - - Latest News -
Nanosonics names new North American president ahead of CORIS launch
November 13, 2025 - - Australian Biotech -
Australians open to AI in healthcare, but prefer doctors to be in control
November 13, 2025 - - Latest News